Shares of BioSpecifics Technologies Corp. (NASDAQ:BSTC) have been given a consensus broker rating score of 1.00 (Strong Buy) from the one brokers that provide coverage for the stock, Zacks Investment Research reports. One analyst has rated the stock with a strong buy recommendation.
Analysts have set a 12 month consensus target price of $85.00 for the company and are anticipating that the company will post $0.72 EPS for the current quarter, according to Zacks. Zacks has also assigned BioSpecifics Technologies an industry rank of 90 out of 256 based on the ratings given to related companies.
A number of equities analysts have commented on the company. Zacks Investment Research raised BioSpecifics Technologies from a “hold” rating to a “buy” rating and set a $72.00 price objective on the stock in a research note on Monday, January 28th. HC Wainwright reaffirmed a “buy” rating and set a $81.00 price objective on shares of BioSpecifics Technologies in a research report on Friday, January 25th. Finally, BidaskClub cut BioSpecifics Technologies from a “strong-buy” rating to a “buy” rating in a research report on Thursday, January 24th.
In related news, Director Paul Gitman sold 5,000 shares of the company’s stock in a transaction that occurred on Wednesday, May 15th. The stock was sold at an average price of $65.83, for a total value of $329,150.00. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Insiders own 21.40% of the company’s stock.
Several hedge funds and other institutional investors have recently made changes to their positions in BSTC. Metropolitan Life Insurance Co. NY lifted its stake in shares of BioSpecifics Technologies by 356.5% during the 4th quarter. Metropolitan Life Insurance Co. NY now owns 2,100 shares of the biopharmaceutical company’s stock valued at $127,000 after buying an additional 1,640 shares in the last quarter. Geode Capital Management LLC increased its position in BioSpecifics Technologies by 6.3% during the fourth quarter. Geode Capital Management LLC now owns 68,017 shares of the biopharmaceutical company’s stock worth $4,121,000 after purchasing an additional 4,056 shares during the last quarter. Assenagon Asset Management S.A. acquired a new stake in shares of BioSpecifics Technologies during the fourth quarter valued at about $1,447,000. Vanguard Group Inc lifted its stake in BioSpecifics Technologies by 1.3% in the third quarter. Vanguard Group Inc now owns 263,100 shares of the biopharmaceutical company’s stock worth $15,389,000 after acquiring an additional 3,433 shares during the last quarter. Finally, BlackRock Inc. lifted its position in shares of BioSpecifics Technologies by 20.4% during the 3rd quarter. BlackRock Inc. now owns 487,149 shares of the biopharmaceutical company’s stock worth $28,493,000 after buying an additional 82,625 shares during the last quarter. 60.69% of the stock is owned by institutional investors and hedge funds.
Shares of BSTC traded up $0.47 during trading hours on Thursday, reaching $63.93. 1,478 shares of the company’s stock traded hands, compared to its average volume of 60,435. The firm has a market capitalization of $461.99 million, a price-to-earnings ratio of 23.37 and a beta of 1.27. BioSpecifics Technologies has a twelve month low of $40.58 and a twelve month high of $73.31.
BioSpecifics Technologies (NASDAQ:BSTC) last announced its quarterly earnings data on Friday, May 10th. The biopharmaceutical company reported $0.60 EPS for the quarter, missing the Zacks’ consensus estimate of $0.62 by ($0.02). BioSpecifics Technologies had a return on equity of 21.08% and a net margin of 59.99%. The business had revenue of $8.13 million for the quarter, compared to analyst estimates of $8.10 million. On average, research analysts expect that BioSpecifics Technologies will post 3 earnings per share for the current fiscal year.
About BioSpecifics Technologies
BioSpecifics Technologies Corp., a biopharmaceutical company, engages in the development of an injectable collagenase clostridium histolyticum for various indications in the United States and internationally. The company offers injectable collagenase for the treatment of Dupuytren's contracture and Peyronie's disease under the XIAFLEX or Xiapex brands.
Featured Story: Why Invest in Dividend Achievers?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for BioSpecifics Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioSpecifics Technologies and related companies with MarketBeat.com's FREE daily email newsletter.